MicroPort Scientific : ® Attends CBS 2017

Nanjing, China - From November 30 to December 3, Shanghai MicroPort Medical (Group) Co., Ltd. ('MicroPort') attended the 10th Left Main & Coronary Bifurcation Summit ('CBS 2017') held in Nanjing of Jiangsu Province, and had in-depth communication with several overseas experts. The CBS 2017 was themed on 'applying big data with well-designed RCT to obtain more clinical evidence for patients,' 'to incorporate new interventional technologies and procedures into the care of patients with complex bifurcation disease,' 'to integrate advances in hemodynamic evaluation and mechanisms into the treatment of patients with coronary bifurcations,' and 'to analyze and compare treatment options for patients with bifurcation lesions.' The summit aims to build an academic exchange platform for Interventional cardiologist regarding the interventional treatment of coronary bifurcation lesions, through reports of the latest clinical trials, case analysis and discussions, as well as operation demonstrations and rebroadcasting.

During the conference, Dr. Ricardo Alves Da Costa from Brazil, Dr. Alfredo E. Rodriguez from Argentina, and Dr. Pierfrancesco Agostoni and Dr. Koen Teeuwen from the Netherlands were invited to complete three cases using Firehawk Rapamycin Target Eluting Coronary Stent System ('Firehawk') in Nanjing First Hospital. Specifically, Dr. Alfredo E. Rodriguez performed a case in which Firehawk was used to treat left anterior descending stenosis lesion, and Dr. Pierfrancesco Agoston and Dr. Koen Teeuwen implanted four Firehawk stents in a complex CTO case. The two cases achieved good postoperative outcome and the physicians spoke highly of the excellent crossability, pushability of Firehawk.

Taking the opportunity of this summit, Dr. Ricardo Alves Da Costa, Dr. Pierfrancesco Agostoni, and Dr. Koen Teeuwen were invited to visit MicroPort and MicroPort Self-Experience Center. They said they were impressed by the incredible innovation ability and diversified business of MicroPort.

This summit further strengthened and promoted the academic exchange and cooperation between China and other countries, and at the same time, it enabled domestic and international experts of interventional therapy to get a deeper understanding in MicroPort and its products. In the future, MicroPort will continue to provide academic exchange platforms for Interventional cardiologists by attending more significant and influential academic events such as the CBS.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]